<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01753232</url>
  </required_header>
  <id_info>
    <org_study_id>TA-DALI-MONET-01-D</org_study_id>
    <nct_id>NCT01753232</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of the DALI LDL-adsorber and MONET Lipoprotein Filter</brief_title>
  <acronym>LINET</acronym>
  <official_title>Non-interventional Study: Safety and Efficacy of the DALI LDL-adsorber and MONET-lipoprotein Filter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care Deutschland GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Medical Care Deutschland GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low Density Lipoprotein (LDL)-apheresis refers to a procedure in which blood taken from a
      patient's vein is cleaned from pathogenic substances, e.g. cholesterol, outside the body and
      then given back to the patient. In the DALI (Direct Adsorption of Lipoproteins)-system whole
      blood is pumped over an adsorber containing beads that selectively bind LDL-cholesterol. The
      MONET (Membrane filtration Optimized Novel Extracorporeal Treatment)-system works with plasma
      which is cleaned by filtration. This study comprises the recording of safety and efficacy
      data from patients treated either with the DALI or MONET-system over a period of 2 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data were recorded from patients suffering from familial hypercholesterolemia and treated by
      lipid apheresis using one of the two systems investigated for at least 3 months prior to
      inclusion in the study. Only those treatments were documented in which routine blood samples
      for laboratory analysis were taken, or in which adverse or serious adverse device effects
      occur.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Low Density Lipoprotein (LDL)-Concentration</measure>
    <time_frame>Every two weeks to every three months for 24 months</time_frame>
    <description>Data are only recorded for visits with lab results</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood/plasma volume treated</measure>
    <time_frame>Every two weeks to every three months for 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of occurence of adverse and serious adverse device effects</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Lipoprotein(a)-concentration</measure>
    <time_frame>Pre/post treatment over 24 months, once per month or every 3 months</time_frame>
    <description>Only in patients with isolated Lp(a) increase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of total cholesterol</measure>
    <time_frame>Every two weeks to every three months for 24 months</time_frame>
    <description>Only for treatment sessions with lab results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of High Density Lipoprotein (HDL)-concentration</measure>
    <time_frame>Every two weeks to every three months for 24 months</time_frame>
    <description>Only for treatment sessions with lab results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of triglyceride-concentration</measure>
    <time_frame>Every two weeks to every three months for 24 months</time_frame>
    <description>Only for treatment sessions with lab results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood count</measure>
    <time_frame>Every two weeks to every three months for 24 months</time_frame>
    <description>Only for treatment sessions with lab results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of fibrinogen-concentration</measure>
    <time_frame>Every two weeks to every three months for 24 months</time_frame>
    <description>Only for treatment sessions with lab results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of creatinine-concentration</measure>
    <time_frame>Every two weeks to every three months for 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Immunoglobulins (Ig)</measure>
    <time_frame>Every two weeks to every three months for 24 months</time_frame>
    <description>Only for treatment sessions with lab results, Immunoglobulin (Ig) G, IgA and IgM if measured. In MONET patients only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C Reactive Protein (CRP)-concentration</measure>
    <time_frame>Every two weeks to every three months for 24 months</time_frame>
    <description>Only for treatment sessions with lab results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of blood pressure and heart rate</measure>
    <time_frame>Every two weeks to every three months for 24 months</time_frame>
    <description>Only for treatment sessions with lab results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood or plasma flow</measure>
    <time_frame>Every two weeks to every three months for 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticoagulation regime</measure>
    <time_frame>Every two weeks to every three months for 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment time</measure>
    <time_frame>Every two weeks to every three months for 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication</measure>
    <time_frame>Every two weeks to every three months for 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">108</enrollment>
  <condition>Hypercholesterolemia, Familial</condition>
  <condition>LIPOPROTEIN TYPES--Lp SYSTEM Lp(a) HYPERLIPOPROTEINEMIA</condition>
  <arm_group>
    <arm_group_label>DALI-adsorber, hypercholesterolemia</arm_group_label>
    <description>Patients suffering from familial hypercholesterolemia treated at least twice a month with the DALI-system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MONET-Filter, hypercholesterolemia</arm_group_label>
    <description>Patients suffering from familial hypercholesterolemia treated with the MONET-Lipoprotein filter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DALI-adsorber</intervention_name>
    <description>Recording of treatment data. No extra interventional treatment</description>
    <arm_group_label>DALI-adsorber, hypercholesterolemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MONET-Lipoprotein filter</intervention_name>
    <description>Only treatment data recording. No extra interventional treatment</description>
    <arm_group_label>MONET-Filter, hypercholesterolemia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hypercholesterolemic patients from free-standing private apheresis centres and one hospital
        department
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  given informed consent

          -  18 years or older

          -  patient compliant to therapy as prescribed

          -  at least two therapy sessions per month

          -  treatment with DALI or MONET system for at least 3 months before inclusion

          -  last severe invasive intervention in hospital more than 3 months ago

        Exclusion Criteria:

          -  earlier participation in the study

          -  unconscious patient/persons without capacity to contract

          -  for DALI: intake of ACE-inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainer Heinzler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gemeinschaftspraxis Gysan, Heinzler, May, Hossmann</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franz Heigl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dres. Heigl, Hettich &amp; Partner Medizinisches Versorgungszentrum</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Leistikow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nierenzentrum Mannheim</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frido Himmelsbach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Apheresezentrum Ingelheim</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ralf Spitthöver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrologische Gemeinschaftspraxis Dialysezentrum/Lipidzentrum</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eberhard Roeseler, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zentrum für Nieren,- Hochdruck und Stoffwechselerkrankungen Standort Heidering</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Volker Schettler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrologisches Zentrum Goettingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerd Schmitz, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Regensburg Department Clinical Chemistry and Laboratory Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nadim Abduhl-Rahman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dialysezentrum Magdeburg-Stadtfeld</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jens Ringel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dialysezentrum Potsdam</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Ramlow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Apheresezentrum Rostock</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nierenzentrum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden Würtemberg</state>
        <zip>68309</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum</name>
      <address>
        <city>Kempten</city>
        <state>Bayern</state>
        <zip>87439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg Institut für Klinische Chemie und Laboratoriumsmedizin</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum Potsdam</name>
      <address>
        <city>Potsdam</city>
        <state>Brandenburg</state>
        <zip>14482</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apheresezentrum Rostock</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>18059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrologisches Zentrum Goettingen</name>
      <address>
        <city>Goettingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Nieren und Hochdruckkrankheiten Standort Heidering</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrologische Gemeinschaftspraxis Dialysezentrum/Lipidzentrum</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein Westfalen</state>
        <zip>45127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Gysan, Heinzler, May, Hossmann</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apheresezentrum Ingelheim</name>
      <address>
        <city>Ingelheim</city>
        <state>Rheinland Pfalz</state>
        <zip>55218</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum Magdeburg-Stattfeld</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen Anhalt</state>
        <zip>39108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2012</study_first_submitted>
  <study_first_submitted_qc>December 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2012</study_first_posted>
  <last_update_submitted>September 3, 2015</last_update_submitted>
  <last_update_submitted_qc>September 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DALI adsorber</keyword>
  <keyword>MONET lipoprotein filter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

